Xcell Biosciences

Kiyatec specializes in modeling and predicting cancer patient response to drug therapies, using ex vivo 3D cell culture technology, in order to inform clinical decision-making and drive drug development. Its predictive clinical tests provide oncologists with patient-specific response profiles to the current standard of care drugs prior to treatment selection. The company was founded in 2005 and is based in Greenville, South Carolina.

PharmaSelex (fka:GPC-Rx) focuses on the structure prediction of G-protein coupled receptors (GPCRs) to develop new GPCR-targeting drugs with reduced toxicity and enhanced selectivity. GPCRs are cell surface receptors that transmit chemical messages across the cell membrane. GPCRs have a complex structure that spans the cellular membrane seven times and is therefore difficult to predict. Due to their mediation of numerous critical physiological functions, GPCRs are involved in major disease areas including cardiovascular, metabolic, neurodegenerative, psychiatric, cancer, and infectious diseases. To facilitate the development of GPCR-targeting drugs, GPC-Rx aims to predict the structures of apo and ligand-bound GPCRs. The structure of GPCRs will permit rational design and optimization of drug candidates of many disease targets. GPC-Rx's technology was developed in the laboratory of Dr. William Goddard Ph.D. at California Institute of Technology. The Goddard group has established and validated methods to generate 3D-structures of GPCRs and their complexes with known ligands.

Chalex Corporation's precision-made chambered McMaster counting slides are used by researchers, laboratories, nematologists and veterinary practitioners throughout the world. Made of clear durable acrylic for long-lasting use, the company's slides also feature exact volumes thanks to injection-molded accuracy which yield consistent test results compared to other slides with handmade chamber spacers. The quality of these slides make them the standard the world over.

NeoClone is a custom monoclonal antibody company focused on developing high quality antibodies for sale as reagents and establishing partnerships and collaborations to develop diagnostic mAbs.

The RDSP was created to help investigators identify funding opportunities and provide assistance to applicants. The RDSP staff work to stimulate research in cancer CAM and design activities that will develop the foundation of the science in cancer CAM research. RDSP programs include a series of Expert Panels on Research Methodologies in Cancer, an Invited Speakers Series, and technical assistance to help investigators prepare grant applications in cancer CAM.

McMillin Pharma is a company seeking to market a high throughput screening method for testing drug libraries in early stage drug development. The technology and screening services of the company are used to predict which drugs may be more effective in later stages of the drug development process by modeling the interactions between tumors and their microenvironment.